Status:
COMPLETED
Adjuvant Radiotherapy for Resected Hepatocellular Carcinoma With MVI
Lead Sponsor:
Eastern Hepatobiliary Surgery Hospital
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
Positive micro vascular invasion in early stage hepatocellular carcinoma(HCC) leads to early recurrence after surgery. Adjuvant external radiotherapy will be applied in those patients to see if diseas...
Detailed Description
Hepatocellular carcinoma(HCC) ranks the 6th most common cancer and is the 2nd leading cause of cancer-related death globally. Surgical resection remains the most efficient therapy in early stage. Thou...
Eligibility Criteria
Inclusion
- solitary nodule;
- tumor adjacent to the main trunk of hepatic vein, cava vena, or to the major branch of portal vein (including the lobar branch at least);
- macro-vascular negative;
- no previous treatment before surgery;
- no previous hepatic surgery;
- Child-Pugh score A for hepatic function.
Exclusion
- spontaneous rupture;
- pathologically proved positive resection margin;
- severe cirrhosis with hypersplenism or esophageal and gastric varices;
- 4-weeks postoperative examination revealed α-fetal protein(AFP) still positive or new lesion in remnant liver;
- postoperative complications required a secondary operation or more than 3 weeks'recovery from surgery.
Key Trial Info
Start Date :
August 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2020
Estimated Enrollment :
76 Patients enrolled
Trial Details
Trial ID
NCT04891874
Start Date
August 1 2015
End Date
December 31 2020
Last Update
September 10 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Second Military Medical University
Shanghai, Shanghai Municipality, China, 200438